Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer

STATUS

Recruiting
End date

Aug 23, 2025
participants needed

600
sponsor

The Greater Poland Cancer Centre

Updated on 23 January 2021

See if I qualify

metastasis

adenocarcinoma

adenocarcinoma of prostate

Summary

The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.

Description

Evaluation of the usefulness expression of selected proteins (PTEN, SMAD4, Cyclin D1, SPP1) as prognostic and predictive factors.

Details

Condition	Malignant neoplasm of prostate, Prostate Cancer, Prostate Cancer, Early, Recurrent, Prostatic disorder, Prostate Disorders, Prostate Disorders, Prostate Cancer, Early, Recurrent, Prostate Cancer, prostate carcinoma, prostate cancers
Treatment	SBRT
Clinical Study Identifier	NCT03225235
Sponsor	The Greater Poland Cancer Centre
Last Modified on	23 January 2021

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	men from 40 to 75 years of age with a confirmed adenocarcinoma prostate, prostate biopsy will be performed <180 days prior to the randomization date
	completed assessment of tumor differentiation according to Gleason grading allows to perform stratification
	general Performance Status according to the Eastern Cooperative Oncology Group (ECOG) classification ( 0 -1)
	belonging to the group of low and intermedium risk of progression; (cT1-cT2c, Gleason 7, PSA to 19.9 ng / ml), cT specified by AJCC 7 Edition (appendix 2)
	PSA marked at least 10 days after or before the biopsy, and for patients taking phytosterol 30 days after discontinuation
	no distant metastases
	signing informed consent
	morphological and biochemical blood parameters within the normal limits
Exclusion Criteria
	the presence of active cancer, except skin cancer preceding period 5 years prior to randomization
	surgical treatment (radical prostatectomy) or RT in the pelvic area
	co-morbidities that may significantly affect the expectancy life of the patients
	do not meet the criteria for inclusion

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

metastasis

adenocarcinoma

adenocarcinoma of prostate

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer